RNA-Dependent Protein Kinase (PKR) Depletes Nutrients, Inducing Phosphorylation of AMP-Activated Kinase in Lung Cancer
RCT STEP 9 - Semaglutide vs Placebo for Knee Osteoarthritis in Patients with Obesity, NEJM (2024) [PubMed abstract] The STEP 9 study enrolled 407 patients with BMI 30 and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain Main inclusion criteria Age 18 years or older BMI 30 ACR diagnostic criteria for knee OA Moderate X-ray changes (Kellgren-Lawrence grade 2 or 3) in target knee Knee OA WOMAC pain score of 40 Main exclusion criteria Use of opioid medications Use of obesity medication within 90 days Knee injection within 90 days Baseline characteristics Average age - 56 years Average weight - 239 lbs (108.6 kg) Average BMI - 40.3 Female sex - 82% Average WOMAC pain score - 70.9 Randomized treatment groups Group 1 (271 patients): Semaglutide 2.4 mg once weekly Group 2 (136 patients): Placebo Semaglutide was started at 0.24 mg once weekly and titrated over 16 weeks to 2.4 mg The percentage change in body weight and the change in the WOMAC pain score (scale 0 - 100, with higher scores meaning worse outcomes) from baseline to week 68 Primary outcome: Results Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo
Li et al used tetrahedral framework nucleic acid (tFNA) to synthesize tFNA-Cur, a nanoparticle that can deliver the natural compound curcumin to the bone marrow, thereby enhancing the bioavailability and stability of curcumin
Indeed, compared to the sham group, LOsG significantly decreased both FoxO1 mRNA and protein expression, as demonstrated by immunohistochemistry analysis (Fig
GLP-1 medications reduce inflammation and improve metabolic health, which can decrease chronic immune activation, one of the major drivers of accelerated aging in people with HIV
Melanotan II is a non-selective agonist of melanocortin receptors
